Key result
Host angiotensin II type 1a receptor deficiency or pharmacological blockade with TCV-116 significantly reduced tumor angiogenesis, slowed tumor growth, and improved survival in mice.
Why the study?
Does AT1 receptor deficiency or blockade reduce tumor angiogenesis and growth in a mouse melanoma model?
Does AT1 receptor deficiency or blockade reduce tumor angiogenesis and growth in a mouse melanoma model?
p-value: p=<0.05
The host ATII-AT1 receptor pathway plays a crucial role in tumor angiogenesis and growth by supporting tumor-associated macrophage infiltration and enhancing VEGF levels.
AT1 blockade should not yet enter oncology practice; leaves open translation of mouse angiogenesis findings to humans.
Although the renin angiotensin system (RAS) is a major regulator of vascular homeostasis, the role of the RAS in tumor angiogenesis is little understood. Here we show that host angiotensin II (ATII) type 1 (AT1) receptor plays an important role in angiogenesis and growth of tumor cells engrafted in mice. Subcutaneous B16-F1 melanoma-induced angiogenesis as assessed by tissue capillary density and microangiography was prominent in WT mice but was reduced in AT1a receptor–deficient (AT1a–/–) mice. Consequently, tumor growth rate was significantly slower, and the mouse survival rate was greater, in AT1a–/– mice than in WT mice. Tumor growth was also reduced in WT mice treated with TCV-116, a selective blocker of AT1 receptor. Because the β-galactosidase gene was inserted into the AT1a gene locus in AT1a–/– mice, the site of β-galactosidase expression represents the AT1a receptor expression in these mutant mice. In tumor-implanted AT1a–/– mice, the major site of the β-galactosidase expression was macrophages in tissues surrounding tumors. Moreover, the number of infiltrated macrophages was significantly lower in AT1a–/– mice than in WT mice, and double-immunofluorescence staining revealed that these macrophages expressed VEGF protein intensively. Therefore, the host ATII-AT1 receptor pathway supports tumor-associated macrophage infiltration, which results in enhanced tissue VEGF protein levels. The host ATII-AT1 receptor pathway thereby plays important roles in tumor-related angiogenesis and growth in vivo.
No takes yet. Share an insight, caveat, or question.
Egami et al. (2003) studied Tumor angiogenesis and growth (Melanoma and Fibrosarcoma) (n=163). AT1a receptor deficiency or TCV-116 (AT1 receptor blocker) vs. Wild-type (WT) mice or untreated WT mice was evaluated on Tumor volume and host survival (p=<0.05). Host angiotensin II type 1a receptor deficiency or pharmacological blockade with TCV-116 significantly reduced tumor angiogenesis, slowed tumor growth, and improved survival in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: